Loading quotes...

Forecast

Buy	15
Hold	8
Sell	2

News Go to news feed

ResMed stock falls after revenue miss and cautious outlook

ResMed reported adjusted EPS of $2.95 for the fourth fiscal quarter, slightly above consensus, but narrowly missed revenue estimates with $1.46 billion. The first-time FY2027 guidance forecasts core revenue growth of only 5–7%, weighed in part by an expected $75 million revenue headwind from a safety action affecting the Astral ventilator series. Investors also expect additional pressure from the planned sale of the MatrixCare software business and the acquisition of Noctrix Health, which are likely to dilute EPS, prompting several analysts to cut price targets. » More on de.investing.com
Resmed to report quarterly results for June 30, 2026 — analysts expect declines

Resmed will release results for the quarter ended June 30, 2026, on August 6, 2026. On average, analysts expect earnings per share of $0.289 and revenue of about $1.46 billion, both well below last year’s figures ($0.400 AUD and $2.10 billion AUD, respectively). For the recently ended fiscal year, consensus estimates are $1.11 earnings per share and about $5.65 billion in revenue versus $1.47 AUD and $7.95 billion AUD in the prior year. » More on finanzen.net
ResMed sells software subsidiary MatrixCare to Frazier Healthcare Partners

ResMed has signed a binding agreement to sell its cloud-based software subsidiary MatrixCare to Frazier Healthcare Partners. MatrixCare provides electronic health records and related solutions for out-of-hospital care providers and serves more than 15,000 providers; financial terms were not disclosed. ResMed says the move is part of its Strategy 2030 and expects the transaction to close in the third quarter of 2026, subject to customary conditions. The company also points to a strong balance sheet and annual revenue of about $5.5 billion. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, ResMed has already paid €0.11 in dividends. The last payout was in September.

Financials

In the last quarter, ResMed had revenue of €1.25bn and net profit of €370.8m

(EUR)	September 2026	YoY
Revenue	1.25bn	10.17%
Gross profit	764.42m	9.29%
Net profit	370.8m	24.85%
EBITDA	447.37m	2.29%

Fundamentals

Metric	Value
Market capitalization	€30.06bn
Number of shares	1.41bn
52-week high/low	€24.66 - €15.75
Dividend yield	0.69%
Dividends TTM	€0.15
Beta	0.74
P/E ratio	21.88
PEG ratio	1.82
P/B ratio	5.78
P/S ratio	5.90

Company profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.